Page 305 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 305
YI P1061 THE MACROPHAGE ACTIVATION MARKER SCD163 AND ePOSTERS
THE APOPTOSIS MARKER CYTOKERATIN-18 ARE BOTH
YI P1062 PREDICTORS OF DISEASE SEVERITY IN PATIENTS WITH
YI P1063 NON-ALCOHOLIC FATTY LIVER DISEASE
YI P1064 Konstantin Kazankov*, Francisco Barrera, Holger J. Møller,
YI P1065 Chiara Rosso, Elisabetta Bugianesi, Ester Vanni, Saeed Esmaili,
YI P1066 Mohammed Eslam, Duncan McLeod, Bo M. Bibby, Hendrik Vilstrup,
Jacob George, Henning Grønbæk, Denmark
IRON METABOLISM IN CHILDREN WITH NONALCOHOLIC
FATTY LIVER DISEASE
Marta Flisiak-Jackiewicz*, Monika Kłusek-Oksiuta, Eugeniusz Tarasów,
Ewa Koc-Żórawska, Małgorzata Wojtkowska, Dariusz Lebensztejn, Poland
EVALUATION OF TRANSIENT ELASTOGRAPHY
(FIBROSCAN®) FOR THE MEASUREMENT OF LIVER
STIFFNESS IN MORBIDLY OBESE PATIENTS BEFORE
BARIATRIC SURGERY
Monika Rau*, Johannes Weiss, Ilona Hering, Gwendolyn Bender,
Christian Jurowich, Theodor Kudlich, Andreas Geier, Germany
ASSOCIATION BETWEEN PNPLA3 I148M POLYMORPHISM
AND NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN
THE INDIAN CONTINENT
Devaraja Rangegowda*, Shwetank Sharma, Chandan Kumar K N,
Rakhi Maiwal, Chitranshu Vashista, Manoj K. Sharma, Vikram Bhatia,
Ajeet S. Bhadoria, Archana Rastogi, Shiv Kumar Sarin, India
LOVASTATIN’S AND PENTOXIFYLLINE’S EFFECTS IN
PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS
Elena C. Rezi*, Romeo Mihaila, Laurentiu Nedelcu, Carmen Domnariu,
Romania
NAFLD, FETUIN-A AND ATHEROSCLEROSIS BURDEN:
DOES VASCULAR TOPOGRAPHY MATTER?
Fabio Nascimbeni*, Dante Romagnoli, Enrica Baldelli, Valentina Sirotti,
Stefano Ballestri, Marco Bertolotti, Amedeo Lonardo, Italy
Vienna, Austria • April 22–26, 2015 305
THE APOPTOSIS MARKER CYTOKERATIN-18 ARE BOTH
YI P1062 PREDICTORS OF DISEASE SEVERITY IN PATIENTS WITH
YI P1063 NON-ALCOHOLIC FATTY LIVER DISEASE
YI P1064 Konstantin Kazankov*, Francisco Barrera, Holger J. Møller,
YI P1065 Chiara Rosso, Elisabetta Bugianesi, Ester Vanni, Saeed Esmaili,
YI P1066 Mohammed Eslam, Duncan McLeod, Bo M. Bibby, Hendrik Vilstrup,
Jacob George, Henning Grønbæk, Denmark
IRON METABOLISM IN CHILDREN WITH NONALCOHOLIC
FATTY LIVER DISEASE
Marta Flisiak-Jackiewicz*, Monika Kłusek-Oksiuta, Eugeniusz Tarasów,
Ewa Koc-Żórawska, Małgorzata Wojtkowska, Dariusz Lebensztejn, Poland
EVALUATION OF TRANSIENT ELASTOGRAPHY
(FIBROSCAN®) FOR THE MEASUREMENT OF LIVER
STIFFNESS IN MORBIDLY OBESE PATIENTS BEFORE
BARIATRIC SURGERY
Monika Rau*, Johannes Weiss, Ilona Hering, Gwendolyn Bender,
Christian Jurowich, Theodor Kudlich, Andreas Geier, Germany
ASSOCIATION BETWEEN PNPLA3 I148M POLYMORPHISM
AND NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN
THE INDIAN CONTINENT
Devaraja Rangegowda*, Shwetank Sharma, Chandan Kumar K N,
Rakhi Maiwal, Chitranshu Vashista, Manoj K. Sharma, Vikram Bhatia,
Ajeet S. Bhadoria, Archana Rastogi, Shiv Kumar Sarin, India
LOVASTATIN’S AND PENTOXIFYLLINE’S EFFECTS IN
PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS
Elena C. Rezi*, Romeo Mihaila, Laurentiu Nedelcu, Carmen Domnariu,
Romania
NAFLD, FETUIN-A AND ATHEROSCLEROSIS BURDEN:
DOES VASCULAR TOPOGRAPHY MATTER?
Fabio Nascimbeni*, Dante Romagnoli, Enrica Baldelli, Valentina Sirotti,
Stefano Ballestri, Marco Bertolotti, Amedeo Lonardo, Italy
Vienna, Austria • April 22–26, 2015 305
